Outcomes and complications associated with off-label and untested use of drug-eluting stents
about
Clopidogrel: an updated and comprehensive reviewLong-term clinical outcomes after drug-eluting and bare-metal stenting in MassachusettsEffects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectivesBiodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomizeSelective versus exclusive use of drug-eluting stents in treating multivessel coronary artery disease: a real-world cohort study.Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic RegistriesDrug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis.Relationship between red blood cell distribution width and intermediate-term mortality in elderly patients after percutaneous coronary interventionMedicare's policy on carotid stents limited use to hospitals meeting quality guidelines yet did not hurt disadvantaged.Sirolimus-eluting stents versus bare-metal stents in routine clinical use: a nonrandomized comparison.On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomesOutcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents.Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry.Safety and effectiveness of drug-eluting stents in Chinese patients with coronary artery disease with off- and on-label indications: results from a single-centre registrySafety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practiceDrug-eluting stents: a review of current evidence on clinical effectiveness and late complications.Use of noninvasive ventilation in patients with acute respiratory failure, 2000-2009: a population-based study.Off-label use of stents: bare-metal versus drug-eluting stents.Drug-eluting stent safety: findings from preclinical studies.A comparison of bare-metal and drug-eluting stents for off-label indications.A critical appraisal of the safety and efficacy of drug-eluting stents.Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment.Local drug delivery for treatment of coronary and peripheral artery disease.Long-term risk of clinical events from stenting side branches of coronary bifurcation lesions with drug-eluting and bare-metal stents: an observational meta-analysis.The management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery.Off-label use of drugs and medical devices: a review of policy implications.Perioperative antiplatelet management in patients with coronary artery stenting.Perioperative management of antiplatelet therapy in patients with drug-eluting stents.Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention.Current status and future trends in drug-eluting stents.Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry.In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.Svelte integrated delivery system performance examined through diagnostic catheter delivery: the SPEED registry.The real world experience of the biodegradable polymer-coated sirolimus-eluting coronary stent system: Results From an "All-Comers" Clinical Experience.Toward defining the role of drug-eluting stents.
P2860
Q28219411-A15427CE-7AA4-4763-ADA2-BA6C97189B8EQ33649631-36AAFB2D-8F26-43E9-9C44-668D8A2DE731Q34159834-2BD58C1C-2C2C-4686-A859-AFA51D56356BQ34207990-B980D601-7BC8-4168-8CB4-D4BBFD56EBCBQ34304853-8574F1C3-6DF1-4CCE-B6DB-A441FBB41198Q34505408-FD6ADA17-7DF2-4601-9092-C9DBBA7EB826Q34773417-25E6FDB1-0B03-4CC7-893E-E2B6259BD3FEQ35019663-0C761811-564C-4B96-9AA4-92D58CCCEE64Q35189884-10E0CC47-5809-47C8-B17C-EF3477C5C3C1Q35594795-D239E5A6-323A-46A6-A479-A3BF049815B1Q35820167-304AD96A-F548-48B6-9DCA-3F87B874382EQ35878281-779E6666-77E3-40CC-91D1-1EA9D18137DDQ36602870-B762BDA3-4547-43AB-BE3D-4CDA87B0E333Q36800865-8A6E4435-21F9-44EC-AC04-2D1A3CF36B63Q37134004-EFB35102-8F96-4F06-94BE-B6F36A0248D4Q37141941-474BF068-0BE8-4954-B603-3BA9837E1B4DQ37192220-8BFF19C8-0AD9-4857-851E-1099409A8ECAQ37269384-39F9ABF8-7046-4587-8802-6E60FD9133C9Q37329149-07E1A150-1465-4B96-A520-3F4C3551981DQ37385456-61CD3379-05FD-4A5A-8C17-40E89D2DA242Q37412922-9A24964E-C305-4F5B-ADE0-806491EA6AF8Q37588002-AC925FF2-70C8-4931-8233-A2883DC38847Q37629184-F0B8D72F-6B1F-407B-9E4C-766DF160B188Q37765610-40370000-9067-4BAA-8756-FE296FB35ACCQ37786302-7133DB02-97E2-4F92-B05D-E80AC60876E6Q37808050-3DBCA6C1-05A1-477C-8B9F-FC8B068C0AF9Q37999651-D05CD373-DF47-4AF1-AB95-5474EF925ADAQ38012080-07A8790A-DE41-4630-ABF1-46B31E2CB0F1Q38084549-D07D779A-0731-4B09-88E9-8788591936C1Q38398230-301763A5-15A6-4E43-8014-EF7A711CE2D5Q39121381-EFA186CC-4D26-4663-A56D-F4157E099446Q40187039-0335A212-A9ED-4C50-91CB-5862E144F389Q42322686-31C91DB8-BB22-46F7-B81D-BF87C171D7FCQ44668746-C18BD548-58DB-45D8-8618-0CF6B1674C10Q45846827-0D15095A-825D-4A08-BBC5-D88B934A5E2BQ45876240-2FB5A5C6-F859-45D3-AF7B-F64073D15696Q45930222-5B9127D3-50A3-44CC-BFF7-5BAAD65B4997Q50640809-80F20C1D-D460-49AA-83BD-425155D8F2B5Q50747273-DC450902-B413-4395-966E-C8602D9EA987Q50944347-E07AB85F-2270-48B4-93D8-7A36F67F4634
P2860
Outcomes and complications associated with off-label and untested use of drug-eluting stents
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Outcomes and complications ass ...... ted use of drug-eluting stents
@ast
Outcomes and complications ass ...... ted use of drug-eluting stents
@en
Outcomes and complications ass ...... ted use of drug-eluting stents
@nl
type
label
Outcomes and complications ass ...... ted use of drug-eluting stents
@ast
Outcomes and complications ass ...... ted use of drug-eluting stents
@en
Outcomes and complications ass ...... ted use of drug-eluting stents
@nl
prefLabel
Outcomes and complications ass ...... ted use of drug-eluting stents
@ast
Outcomes and complications ass ...... ted use of drug-eluting stents
@en
Outcomes and complications ass ...... ted use of drug-eluting stents
@nl
P2093
P3181
P356
P1476
Outcomes and complications ass ...... ted use of drug-eluting stents
@en
P2093
Charles J Davidson
Charles L Bennett
David O Williams
Helen Aslanidou Vlachos
James D Flaherty
Keith H Benzuly
Kevin E Kip
Lynne Goodreau
Mark J Ricciardi
Nirat Beohar
P304
P3181
P356
10.1001/JAMA.297.18.1992
P407
P577
2007-05-09T00:00:00Z